# Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

> **NCT03997123** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 923 (actual)

## Conditions studied

- Triple Negative Breast Neoplasms

## Interventions

- **DRUG:** Capivasertib
- **DRUG:** Paclitaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03997123
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-25
- **Primary completion:** 2026-03-16
- **Final completion:** 2026-03-16
- **Target enrollment:** 923 (ACTUAL)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03997123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03997123, "Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03997123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*